Gemelli Biotech is a specialty biotechnology company that strives to achieve a thriving global family of healthy individuals by unlocking the potential of the microbiome. Gemelli’s mission is to support the discovery of novel diagnostics and therapeutics for the human microbiome by bringing biotechnology innovations to market in a fiscally responsible and socially conscious way.
Gemelli Biotech is proud to partner closely with Cedars-Sinai Medical Center in Los Angeles, ranked by US News and World Report as one of the top 10 hospitals in the nation. The Medically Associated Science and Technology (MAST) program at Cedars-Sinai is dedicated to the development of lab tests, drugs and devices to diagnose and treat patients and works closely with Gemelli. Alignment with MAST allows Gemelli to operate on the cutting edge, with an early look at the newest scientific discoveries related to the microbiome.
In the fall of 2018, Gemelli launched ibs-smart, the groundbreaking blood test for Mixed-Type and Diarrhea Predominant Irritable Bowel Syndrome. An exciting pipeline of innovation is set to follow in 2019.
Gemelli Biotech is proud to partner closely with Cedars-Sinai Medical Center in Los Angeles, ranked by US News and World Report as one of the top 10 hospitals in the nation. The Medically Associated Science and Technology (MAST) program at Cedars-Sinai is dedicated to the development of lab tests, drugs and devices to diagnose and treat patients and works closely with Gemelli. Alignment with MAST allows Gemelli to operate on the cutting edge, with an early look at the newest scientific discoveries related to the microbiome.
In the fall of 2018, Gemelli launched ibs-smart, the groundbreaking blood test for Mixed-Type and Diarrhea Predominant Irritable Bowel Syndrome. An exciting pipeline of innovation is set to follow in 2019.
Location: United States, North Carolina, Raleigh
Employees: 11-50
Total raised: $20.85M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 18.07.2022 | Blue Ox He... | blueoxhcp.... |
| - | Emerging T... | etpvc.com |
| - | Carolina A... | carolinaan... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.06.2022 | Series A | $19M | - |
| 01.07.2019 | - | $1.85M | - |
Mentions in press and media 4
| Date | Title | Description |
| 23.06.2022 | Startups and VCs should be preparing for the possibility of stagflation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. The last time stagflation hit the U.S., “startup” was a niche term, VC an obscure cottage industr... |
| 22.06.2022 | Gemelli Biotech Completes $19 Million Series A Financing Funding to accelerate commercialization of its trio-smart® and ibs-smart® precision diagnostic tests for IBS and SIBO | Gemelli Biotech Corp. (“Gemelli”), a company focused on improving health by providing precision diagnostics for gastrointestinal (GI) diseases, today announced the completion of a $19 million Series A financing. Blue Ox Healthcare Partners ... |
| 22.06.2022 | Gemelli Biotech Closes $19M Series A Financing | Gemelli Biotech, a Los Angeles, CA and Raleigh, NC-based company focused on improving health by providing precision diagnostics for gastrointestinal (GI) diseases, raised $19M in Series A funding. The round was led by Blue Ox Healthcare Par... |
| 01.07.2019 | Gemelli Biotech Picks Up $1.85M In Ongoing Funding | Los Angeles-based Gemelli Biotech, a startup focused on discovery of novel diagnostics and therapeutics for the human microbiome, has raised $1.85M, as part of an ongoing $3.0M fundraising effort for the startup, according to a regulatory f... |